Electromed, Inc.
ELMD Healthcare Medical Devices
Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow ELMD
Electromed, Inc. (ELMD) EV/Sales
As of 16 October 2026, Electromed, Inc. (ELMD) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 0.5× (January 2016) to 4.9× (July 2026); the current reading is higher than 83% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 4.5× | 66.85% |
| FY2025 | 2.7× | 38.25% |
| FY2024 | 1.9× | 10.53% |
| FY2023 | 1.8× | (1.99%) |
| FY2022 | 1.8× | (25.45%) |
| FY2021 | 2.4× | (34.96%) |
| FY2020 | 3.7× | 210.55% |
| FY2019 | 1.2× | (13.74%) |
| FY2018 | 1.4× | (12.44%) |
| FY2017 | 1.6× | 31.85% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.5× | 82.16% |
| Mar 2026 | 2.5× | (25.82%) |
| Dec 2025 | 3.3× | 14.68% |
| Sep 2025 | 2.9× | 7.68% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.7× |
| RXST RxSight, Inc. compare | 0.0× |
| TMCI Treace Medical Concepts, Inc. compare | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. | 2.8× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| PROF Profound Medical compare | 9.9× |
| CATX Perspective Therapeutics, Inc. compare | 64.7× |
| QSI Quantum-Si Incorporated compare | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)